Transcriptional profiling of proliferative skeletal muscle mononucleated cells coupled with broadband electrical cytometry towards diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome…

Active Project Grant Awarded Last action

Award ID
R21NS139044
Recipient
Awarding agency
Obligated
$390,178

Award facts

Completion date 73% complete
Originally
Place of performance
Fountain Hill, PA 18015, USA

Award details come from USAspending.gov.

Description

Transcriptional profiling of proliferative skeletal muscle mononucleated cells coupled with broadband electrical cytometry towards diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome project summary / abstract myalgic encephalomyelitis/chronic fatigue syndrome (me/CFS) is a debilitating, acquired disease affecting up to 2.5 million americans. With increasing evidence that a proportion of patients with covid-19 experience prolonged convalescence and chronic symptoms similar to me/CFS, IT is suggested that the incidence of me/CFS will increase significantly. Currently, no single biomarkers or pathognomonic signs have been identified for diagnostic measures. Instead, diagnosis is based on clinical symptoms after exclusion of other possible etiologies known to cause fatigue, a method that does not prescribe adequate sensitivity or specificity. Since clinical symptoms suggest that skeletal muscle is a major and consistent target of the pathology, and proliferative skeletal mononucleated cells (SMMCS) are excellent indicators of muscle disorders, we hypothesize that proliferative SMMCS from of me/CFS patients are distinguishable from those of healthy individuals on the molecular and cellular level. Proposed work will investigate gene expression, functional pathways and electrical characteristics of single SMMCS from me/CFS and healthy donors to identify a matrix of molecular and biophysical markers to enable future development of diagnostics. Single-cell mrna profiling will identify differential gene expression describing alterations that occur in me/CFS samples. Using differential biomarkers identified by scrna-SEQ, subpopulations of SMMCS unique to me/CFS will be sorted to study changes in protein expression and cell function. Furthermore, an impedance cytometer recently developed by our team will be used to measure single cell electrical spectra, and disease-specific signatures will be identified by machine learning. The molecular, cellular and electrical characteristics will be further correlated with each other to provide a comprehensive understanding of the smmc pathology in me/CFS, an untapped subject. The proposed single- cell transcriptome analysis of SMMCS from me/CFS patients represents the first study of its kind and will greatly contribute to the fundamental knowledge of the role of proliferative SMMCS in me/CFS dysfunctions. Compared to molecular approaches, proposed impedance cytometry captures a 'big picture' of the multitude of changes contributing to abnormalities in me/CFS SMMCS. As specific molecular markers have not been identified for diagnostic measures, the holistic electrical characteristics of single cells offer a unique perspective of global changes in SMMCS and hold great diagnostic potential in the future. Integration of electrical and biological studies of SMMCS will further allow interpretation of the impedance spectra to promote sensing specificity.

Transactions

Action Obligated Date
Amendment $0
Original award $390,178

Subawards

Subrecipient Amount Awarded
Universita' Degli Studi G. D'annunzio DI Chieti-Pescara Co-investigator of this project, Dr. Tiziana Pietrangelo is an Associate Professor of Physiology at the University of G. D’Annunzio Chieti-Pescara, Italy. She… $58,000
Universita' Degli Studi DI Padova Co-investigator of this project, Dr. Tiziana Pietrangelo is an Associate Professor of Physiology at the University of G. D’Annunzio Chieti-Pescara,… $58,000

Quick answers

Who received award R21NS139044?

R21NS139044 was awarded to Lehigh University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 4, 2024.

How much is award R21NS139044 worth?

$390,178 has been obligated on R21NS139044.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award